BliNK Therapeutics is a spin-out from Cancer Research Technology, the commercial arm of Cancer Research, UK, with financial support from Paris based Kurma Life Sciences Partners, to generate monoclonal antibodies.
BliNK Therapeutics Ltds technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at London Research Institute, Cancer Research UK.
BliNK Therapeutics is a spin-out from Cancer Research Technology, the commercial arm of Cancer Research, UK, with financial support from Paris based Kurma Life Sciences Partners, to generate monoclonal antibodies.
BliNK Therapeutics Ltds technology has been developed by Facundo Batista, Head of the Lymphocyte Interaction Laboratory at London Research Institute, Cancer Research UK.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/blink-therapeutics” connections=”true” suffix=””]
BliNK Therapeutics technology provides a new way of activating the immune systems B cells to produce antibodies in response to a specific antigen even when the Çparent B cells are rare or when the antigens are hard for B cells to detect.
In Dec 2014, Valneva SE and BliNK Therapeutics Ltd created a new private company BliNK Biomedical SAS with headquarter at Lyon, France to combine both companies validated antibody discovery platforms to develop proprietary human antibodies targeting immuno-oncology and oncology up to clinical stages.
Recover your password.
A password will be e-mailed to you.